XORTX Therapeutics Inc. (NASDAQ:XRTX) Stock Short Interest Climbs 424.5%

XORTX Therapeutics Inc. (NASDAQ:XRTX) saw a significant growth in short interest in September. As of September 15th, there was short interest totaling 76,755 shares, a growth of 424.5% from the August 31st total of 14,635 shares. Currently, 4.5% of the shares of the stock are short sold. Based on an average trading volume of 367,812 shares, the short-interest ratio is currently 0.2 days.

XORTX Therapeutics Price Performance

Shares of NASDAQ:XRTX traded down $0.03 during trading hours on Friday, hitting $1.69. 46,669 shares of the company’s stock traded hands, compared to its average volume of 686,587. XORTX Therapeutics has a 1 year low of $1.59 and a 1 year high of $7.05. The business has a fifty day moving average price of $2.08 and a 200-day moving average price of $2.19. The firm has a market capitalization of $3.08 million, a P/E ratio of -0.62 and a beta of 0.75.

XORTX Therapeutics (NASDAQ:XRTX) last issued its earnings results on Saturday, August 15th. The technology company reported ($1.05) earnings per share (EPS) for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of XORTX Therapeutics in a research note on Monday. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

XORTX Therapeutics Company Profile

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapies for diseases associated with abnormal uric acid metabolism and progressive kidney injury. The company’s research is centered on reducing uric acid production and addressing the role of uric acid in inflammation and renal disease.

XORTX’s development programs include XRx-008 for autosomal dominant polycystic kidney disease, a genetic condition that causes cysts to form in the kidneys, as well as programs investigating xanthine oxidase inhibition in other kidney-related conditions.